200 related articles for article (PubMed ID: 32875608)
1. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
[TBL] [Abstract][Full Text] [Related]
2. High Mutation Frequency of the
Loeff FC; Falkenburg JHF; Hageman L; Huisman W; Veld SAJ; van Egmond HME; van de Meent M; von dem Borne PA; Veelken H; Halkes CJM; Jedema I
J Immunol; 2018 Mar; 200(6):2199-2208. PubMed ID: 29427418
[TBL] [Abstract][Full Text] [Related]
3. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
Taylor VC; Sims M; Brett S; Field MC
Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
[TBL] [Abstract][Full Text] [Related]
4. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
5. Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
Loeff FC; Rijs K; van Egmond EHM; Zoutman WH; Qiao X; Kroes WGM; Veld SAJ; Griffioen M; Vermeer MH; Neefjes J; Frederik Falkenburg JH; Halkes CJM; Jedema I
Am J Hematol; 2019 Jan; 94(1):93-102. PubMed ID: 30370942
[TBL] [Abstract][Full Text] [Related]
6. Clonal Cell Proliferation in Paroxysmal Nocturnal Hemoglobinuria: Evaluation of
Park J; Kim M; Kim Y; Han K; Chung NG; Cho B; Lee SE; Lee JW
Ann Lab Med; 2019 Sep; 39(5):438-446. PubMed ID: 31037862
[TBL] [Abstract][Full Text] [Related]
7. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract][Full Text] [Related]
8. CD52/GPI- T-Cells Are Enriched for Alloreactive Specificity and Predict Acute Graft-Versus-Host-Disease After Stem Cell Transplantation.
Kinsella FA; Inman CF; Croft W; Zuo J; Pearce H; Barbieri S; Craddock C; Malladi R; Moss P
Transplant Cell Ther; 2021 Jun; 27(6):475.e1-475.e9. PubMed ID: 33863699
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract][Full Text] [Related]
10. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
11. Identification of acquired PIGA mutations and additional variants by next-generation sequencing in paroxysmal nocturnal hemoglobinuria.
Li J; Lin Y; Chen L; Qin L; Tan H; Zou J; Zhang D; Nie Y; Wang G; Zhang H; Liu E; Chen X; Ru K
Int J Lab Hematol; 2020 Aug; 42(4):473-481. PubMed ID: 32359022
[TBL] [Abstract][Full Text] [Related]
12. [Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab].
Ueki D; Yoshida C; Tsutsumi Oota I; Seki M; Komeno T; Ito H; Ide Y
Gan To Kagaku Ryoho; 2019 May; 46(5):913-915. PubMed ID: 31189814
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
[TBL] [Abstract][Full Text] [Related]
15. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
16. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract][Full Text] [Related]
17. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
18. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract][Full Text] [Related]
19. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
20. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
Vivekanandarajah A; Atallah JP; Gupta S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
